SVB Securities analyst David Risinger reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) on June 30 and set a price target of $341.00. The company’s shares closed last Friday at $324.71, close to its 52-week high of $330.85.
According to TipRanks.com, Risinger is a 2-star analyst with an average return of 0.2% and a 50.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $326.50 average price target, representing a 0.8% upside. In a report issued on June 28, J.P. Morgan also maintained a Buy rating on the stock with a $355.00 price target.
The company has a one-year high of $330.85 and a one-year low of $220.20. Currently, Eli Lilly & Co has an average volume of 3.02M.
Based on the recent corporate insider activity of 142 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
Read More on LLY: